MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
Open Access
- 18 April 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8), 2831
- https://doi.org/10.3390/ijms21082831
Abstract
Mismatch repair genes mutS homologs 6/2 (MSH6/2) expressions are involved in tumor growth and programmed cell death 1 ligand 1 (PD-L1) expression in tumor immunity, but the direct association with pituitary adenomas (PAs) is not well understood. We aimed to clarify the effects of MSH6/2 and PD-L1 expression on tumor proliferation and invasiveness in nonfunctioning (NF) PAs. We performed immunohistochemistry to classify the NFPAs into gonadotroph adenoma (GAs), silent corticotroph adenomas (SCAs), null cell adenoma (NCAs), and pituitary transcription factor 1 (PIT1) lineage PAs. We evaluated MSH6/2 and PD-L1 mRNA expressions in NFPAs by real-time PCR (n = 73), and statistically analyzed the expressions and clinicopathological factors. We also investigated the effect of MSH6 knockout on PD-L1 expression in AtT-20ins and GH3. MSH6/2 expressions were significantly lower in invasive NFPAs than in non-invasive NFPAs, and lower in SCAs and NCAs than in GAs. MSH6/2 expressions were positively associated with PD-L1 expression. PD-L1 expression was significantly lower in invasive NFPAs than in non-invasive NFPAs, and lower in SCAs and NCAs than in GAs. Although MSH6/2 expressions also tended to be lower in PIT1 lineage PAs than in GAs, PIT1 lineage PAs expressed PD-L1 equivalently to GA, which was unlike SCAs and NCAs. MSH6 knockout in AtT-20ins and GH3 significantly decreased PD-L1 expression (75% and 34% reduction, respectively) with cell proliferation promotion. In conclusion, differences in MSH6/2 and PD-L1 expressions of SCAs, NCAs, and PIT1-lineage PAs from those of GAs appear to contribute to their clinically aggressive characteristics, such as more proliferation and invasiveness.Funding Information
- Japan Society for the Promotion of Science (JSPS KAKENHI : JP18K16243)
This publication has 40 references indexed in Scilit:
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsCancer Discovery, 2013
- Correlation Between Histological Subtypes and MRI Findings in Clinically Nonfunctioning Pituitary AdenomasEndocrine Pathology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Mismatch repair deficient colorectal cancer in the era of personalized treatmentNature Reviews Clinical Oncology, 2010
- A STUDY OF THE CORRELATION BETWEEN MORPHOLOGICAL FINDINGS AND BIOLOGICAL ACTIVITIES IN CLINICALLY NONFUNCTIONING PITUITARY ADENOMASNeurosurgery, 2007
- High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, BelgiumJournal of Clinical Endocrinology & Metabolism, 2006
- Mechanisms of Disease: the pathogenesis of pituitary tumorsNature Clinical Practice Endocrinology & Metabolism, 2006
- Mechanisms for pituitary tumorigenesis: the plastic pituitaryJCI Insight, 2003
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002
- Pituitary Adenomas with Invasion of the Cavernous Sinus SpaceNeurosurgery, 1993